ESTRO35 Programme Book

SATURDAY 30 APRIL 2016

17:20 > Management of patients with extensive-stage small-cell lung cancer: A European survey of practice K. Haslett (UK), D. De Ruysscher, R. Dziadziuszko, M. Guckenberger, C. Le Pechoux, U. Nestle, C. Faivre-Finn

OC-0140

Proffered Papers CLINICAL 4: LATE BREAKING ABSTRACTS 16:30 - 17:30 | GIALLA

Chair: L. Kepka (Poland) Chair: U. Nestle (Germany)

16:30 > Does an integrated boost increase acute toxicity in prone hypofractiona- ted breast irradiation?

L. Paelinck, A. Gulyban, F. Lakosi, T. Vercauteren, W. De Gersem, B. Speleers, C. Monten, T. Mulliez, P. Berkovic, A. Van Greveling, P. Coucke, W. De Neve, L. Veldeman (Belgium)

OC-0141

16:40 > Hypo- vs normofractionated radiation of early breast cancer in the randomised DBCG HYPO trial

B.V. Offersen (Denmark), E.H. Jacobsen, M.H. Nielsen, M. Krause, L. Stenbygaard, I. Mjaaland, A. Schreiber, U.M. Kasti, M.B. Jensen, J. Overgaard

OC-0142

16:50 > A Bayesian randomisation trial of IMRT vs. PSPT for locally advanced non-small cell lung carcinoma

Z. Liao (USA), J. Lee, R. Komaki, D. Gomez, M. O’Reilly, P. Allen, F. Fossella, J. Heymach, N. Choi, T. Delaney, S. Hahn, C. Lu, J. Cox, R. Mohan

OC-0143

17:00 > Maximum response and PCI are important prognostic factors in LD SCLC patients staged with cMRI C. Eze (Germany), O. Roengvoraphoj, M. Niyazi, S. Gerum, G. Hildebrandt, R. Fietkau, C. Belka, F. Manapov OC-0144

17:10 > Preoperative radiotherapy with an integrated boost compared to chemoradiotherapy for rectal cancer

M. De Ridder (Belgium), A. De Paoli, E. Delmastro, F. Munoz, S. Vagge, D. Norkus, H. Everaert, G. Tabaro, E. Garibaldi, U. Ricardi, E. Borsatti, T. Gevaert, P. Gabriele, G. Boz, A. Sermeus, M.A. MahéB. Engels

OC-0145

SCIENTIFIC PROGRAMME | PROGRAMME AND EXHIBITION GUIDE

81